Abstract
We used a 10-question self-report questionnaire, Mini Voice Questionnaire (MVQ), for mapping the phenomenology of auditory verbal hallucinations (AVH). The MVQ contains questions related to daily AVH frequency and duration, the events preceding AVH episode onset and offset, the very first AVH episode, emotional content, coping strategies, if the voice comes from the inside or outside of head, if it is one’s own voice heard, and whether the voice is present when filling out the questionnaire. Forty-one patients with a diagnosis of schizophrenia spectrum disorder participated in the study. The construction of the MVQ was originally driven by an interest in whether AVH-episode onsets and offsets, that is, the coming and going of the voice, are initiated by specific environmental events or mental states, or whether they occur spontaneously, which could have both theoretical and clinical implications. MVQ scores were correlated with PANSS and BAVQ questionnaire scores. The results showed that specific events do not precede onset or offset of AVH episodes except for the very first episode which was often associated with trauma or other negative events. This finding could have implications for neurobiological models of AVH, showing that AVH episodes are spontaneously initiated, pointing to a neuronal origin of AVH episode onsets and offsets. The P3 (hallucinatory behavior) item of the PANSS questionnaire correlated significantly with frequency and duration of AVH episodes: More frequent and longer AVH episodes were associated with higher P3 scores, implying more severe symptoms. The results are discussed in terms of recent AVH models.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research reported in this paper was funded by an Advanced Grant from the European Research Council (ERC) #693124, and from the Western Norway Health Authorities Grant #912045
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance was provided from the European Research Council Executive Agency (ERCEA #693124) and from the Regional Committee for Medical Research Ethics in Western Norway (REK-Vest #2106/800)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to clinical data regulations imposed by the Western Norway Ethical Committee (REK-Vest) (https://rekportalen.no/#hjem/home), data can be shared by request to Kenneth Hugdahl, and after written permission from the REK-Vest.
